BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer 

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. The company recently “completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (‘NSCLC’) patients,” reads a recent article. “Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence,” Lantern Pharma CEO and President Panna Sharma was quoted as saying. “This achievement builds momentum as we continue enrollment in Taiwan and the United States, bringing us closer to generating the clinical data that could establish LP-300 as a treatment option for this underserved patient population with significant unmet medical need.”

To view the full article, visit https://ibn.fm/eJM3g

About Lantern Pharma Inc.

Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN